Johnson & Johnson Innovation Announces Collaborations with Two Canadian Early-Stage Drug Technology Development Centers Business Wire MONTREAL & TORONTO -- December 10, 2013 Johnson & Johnson Innovation and its affiliate Janssen Inc. in Canada today announced new collaborations with two Canadian early-stage drug technology development centers, Montreal-based NEOMED and Toronto-based MaRS Innovation, to identify and advance promising bio/pharmaceutical technologies that have the potential to impact human health. Through these collaborations, technical experts from the Johnson & Johnson Innovation Center in Boston, Massachusetts will work with NEOMED and MaRS Innovation to identify investment opportunities emerging from well-validated scientific research discoveries within their communities of academic institutions and biotechnology companies. “We know from our history of engagement that the Canadian bio/pharmaceutical environment is one of the most vibrant in the world,” said Robert Urban, Head of the Johnson & Johnson Innovation Center, Boston. “These new collaborations will allow us to potentially advance important new clinical candidates against disease.” “Quebec and Ontario are home to numerous world-class academic and biomedical research enterprises,” said Paul Kershaw, Vice President of Medical Affairs, Janssen Inc. in Canada. “These new relationships with NEOMED and MaRS Innovation are an extension of our commitment to Canada’s innovative research community.” NEOMED is a not-for-profit, public-private Pharma alliance dedicated to drug discovery and development. Partially funded by the Ministère des Finances et de l’Économie du Québec, NEOMED is within the NEOMED Institute, a state-of-the-art R&D facility in the Montréal Technoparc. MaRS Innovationis the commercialization agent for Ontario’s discovery pipeline from16 leading academic institutions. MaRS Innovation is supported by the Government of Canada through theNetworks of Centres of Excellence, by the Government of Ontario through theOntario Centres of Excellence, and by its 16 member institutions. About Johnson & Johnson Innovation The Boston Innovation Center is part of Johnson & Johnson Innovation, a division of Johnson & Johnson Finance Corporation. Johnson & Johnson Innovation focuses on accelerating early innovation and enhancing opportunities for collaboration and investment across Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies focused on early-stage opportunities a one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and diagnostics and consumer companies of Johnson & Johnson. Johnson & Johnson Innovation includes local deal-making capabilities with the flexibility to adapt deal structures to match early-stage opportunities and establish novel collaborations that speed development of those innovations to solve unmet needs in patients. Follow us @jnjinnovation on Twitter. Please visit www.jnjinnovation.com for more information. About Janssen Inc. Janssen is dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, metabolic and chronic diseases and women’s health. Driven by our commitment to patients, we bring innovative products, services and solutions to people throughout the world. Janssen Inc. in Canada is part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Please visit http://www.janssen.ca for more information. Contact: Johnson & Johnson John Lacey, 781-392-5514 jlacey1@ITS.JNJ.com or Feinstein Kean Healthcare Jessica Rowlands, 202-729-4089 email@example.com
Johnson & Johnson Innovation Announces Collaborations with Two Canadian Early-Stage Drug Technology Development Centers
Press spacebar to pause and continue. Press esc to stop.